ODD
ODDITY Tech Ltd. Class A Ordinary Shares
Mentions (24Hr)
0.00% Today
Reddit Posts
Top 4 Spinal Injury Stocks for 2024 ((TSXV: NRX, NYSE: NVRO, NYSE: SYK, NYSE: BSX)
Undervalued Israeli Biotech : NurExone Biologic Inc (TSXV: NRX)
Undervalued Israeli Biotech : NurExone Biologic Inc (TSXV: NRX)
Top 4 Spinal Injury Stocks for 2024 ((TSXV: NRX, NYSE: NVRO, NYSE: SYK, NYSE: BSX)
Undervalued Israeli Biotech : NurExone Biologic Inc (TSXV: NRX)
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment (TSXV: NRX, FSE: J90, NRX.V)
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment (TSXV: NRX, FSE: J90, NRX.V)
Mentions
Yes, there are plenty of quality growth stocks using the applications of Teck in other industries. Examples would be, ODD HOOD RKLB TOST.
ODD has been on a nice little run. Always great when stuff you own gets some steam. Like NRDS has been on a solid run. Same with AMTM.
Things to be thankful for: 1. Berkshire +7% since buying 2. Google +16% since buying (yeah I was late) 3. ODD +14% since buying
A lot of smaller names also have very high short interest though. Including growing and profitable names. ODD is at 11%. UFPT is at 15%. There's more than active selling, there's active shorting.
My current individual stock holdings are BRK.B, GOOG, and ODD Thots?
Seems like what is keeping ODD down are a bunch of analyst price target reductions. GS reasoning was due to “consumer weakness” - This hasnt been the case yet for ODD
Watching $ODD get trampled after that great earnings is nuts. Straight back to the downward trend.
Man it’s wild sometimes owning individual stocks and learning to stomach volatility. Like ODD is up like 15% today. That’s basically a good year of SP gains in one day for an asset. Also biggest thing is knowing what you buy. Helps when holding when going down.
A few notes on ODD after coming down from an earnings high... We're probably going to see increasing cash burn with methodIQ launching. Fortunately the company has been hoarding cash, but the cash flow might look ugly for a few quarters. Ditto brand 4. Looks like a gap up to $45 or so, which has been a big volume area historically. Wouldn't be surprised to see it touch $50. Also sort of expecting it to bounce around between $44-50 range for awhile while the technicals shore up a bit. I had fair value around $60 going into earnings. After running some numbers last night I'm more in the $60-65 range. More upside is there, but cash burn is worth watching. Even blowing all their cash on marketing I still think $60 is fair, plus 20% growth there after as the company grows.
It's actually one that I trimmed back when it was over $70, so some of my cheapest shares are gone. Bought plenty down here though! It's also a great rest of conviction. Like, ODD went from $75 to $37. You have to have conviction there. It's turned me on to starter positions, really see how a drawdown feels.
ODD raising 2025 guidance is baller. There are 6 weeks left in the year, and they're raising. Guiding $2.10/share on the low end. $12 cash per share, no debt. That was 11.9x EV/Earnings leading into this report. Growing 25% annually.
$ODD **Q3 net revenue $148M (+24% YoY)** and **nine-month net revenue $657M (+26% YoY)**. Q3 gross profit was $106M and gross margin improved to **71.6% (+170 bps)**. Q3 adjusted EBITDA was **$29M** and nine-month adjusted EBITDA was **$151M**. Q3 net income was **$18M** and adjusted net income was **$25M (+26% YoY)**. Cash, equivalents and investments totaled **$793M** with **$200M** undrawn credit facilities as of Sept. 30, 2025. The company raised full-year 2025 outlook to **$806–809M revenue**, gross margin \~**72.5%**, adjusted EBITDA **$161–163M**, and adjusted diluted EPS **$2.10–2.12**. METHODIQ brand formally launched in November 2025. * **Q3 net revenue** $148M (+24% YoY) * **Nine‑month net revenue** $657M (+26% YoY) * **Gross margin** 71.6% (+170 bps YoY) * **Cash and investments** $793M with $200M undrawn credit * **Q3 net income margin** 12.0% (down from 14.9% YoY) * **Adjusted EBITDA margin** 19.5% (down 140 bps YoY) * **Q4 adjusted EBITDA guidance** $10–12M (lower quarterly midpoint) “ODDITY delivered strong third quarter results, including financial performance that once again exceeded our guidance across revenue, profit, and earnings per share,” said Oran Holtzman, ODDITY co-founder and CEO. “We are well positioned for a strong finish in 2025 with multiple engines to drive future growth, and we continue to invest in new brands, ODDITY Labs, and tech innovation.” “We achieved a major milestone this week with the official launch of our newest brand: METHODIQ,” Holtzman continued. “Our goal with METHODIQ is to transform a broken medical care system with precise treatments, pioneering technology, and the highest standard of care. This is the next frontier for ODDITY, harnessing the power of our data and technology platform to offer medical grade solutions for our users.”
I was buying NATL recently, I think it's super cheap and they're turning on the buyback machine, which is really helpful in this environment. SJT is interesting with nat gas being hot. When they restart the dividend I expect good things. I've also been buying ODD. Chart is terrible, but I can't resist adding to my position down here. It's too cheap. Otherwise I'm being very discerning right now. Everything I look at has a Terrible chart and I'm not particularly bullish. CCOI is cheap, but plummeting. SHLS is interesting, but not super cheap. ABL is dirt cheap, but I own a ton already. CRMD is one I'n really interested in, but I'm still evaluating it. It looks too obvious and I'm sure I'm missing something.
ODD lots with a great episode on the politics of AI, found [here](https://open.spotify.com/episode/7DifQVNr0WxbAVJF7fH4ua?si=8F_lhR_VSIy1aYGB1SdtHg). I've been watching this bubble and I'm fairly convinced this could be a big driver of future business. For example, there's going to be huge pressure on politicians to bring down electricity rates to pre AI levels. Worth a listen.
Oddity Tech (ODD) said Tuesday it launched Methodiq, a telehealth platform that provides tailored treatments through online diagnosis, removing the need for in-person doctor visits or pharmacy trips. The platform debuts with online treatments for acne, hyperpigmentation and eczema, with plans to expand into additional medical areas. Developed with board-certified dermatologists, Methodiq uses AI-based skin analysis, computer-vision progress tracking and a mix of prescription and non-prescription treatments to support online dermatology care. Methodiq launches with 28 core products and more than 100 personalized treatment plans, including formulations that feature proprietary ingredients from Oddity Labs, according to the company.
ODD officially launching MethodIQ, previously referred to as brand 3. The goal is to launch personalized skin health products. Curious to see how this works out. I still think the market hasn't priced in any gain out of brand 3 and 4, much less the existing brands.
[https://investors.oddity.com/news-releases/news-release-details/oddity-launches-methodiq-telehealth-platform-reimagining-medical](https://investors.oddity.com/news-releases/news-release-details/oddity-launches-methodiq-telehealth-platform-reimagining-medical) >ODDITY Tech Ltd. (NASDAQ: ODD) today announced the launch of METHODIQ, a medical telehealth platform delivering customized, high-efficacy treatments powered by online diagnosis – without needing to go to a doctor’s office or get lost in a drug store.
Thank you Mr Market for letting me finish my ODD position
I post pretty frequently (probably too much). I've been pitching ODD for over a year when it gets cheap. If it traded at similar valuation to its peers it should be around $60, minimum. It's also launching some really interesting new lines. I'm incredibly bullish on this one, though I don't think it has instant multi-bagger potential. ABL should be a $15-18 stock, plus it's growing at insane rates. SJT is my other recent buy. It's a trust that owns a ton of natural gas reserves. Their royalty structure is that they only get a portion of profits, not revenue (like TPL does) and their tenant has been investing in Capex for awhile and this not making any "profits". The capex is ending and even at current nat has prices SJT will likely pay out $1/share in dividends, or about a 16% yield. Normally the stock trades around 4-5% yield, which would imply a share price around $18. It's currently at $6. So I've been buying that. I still think BW is a $15-20 stock, even if they don't announce any new business.
Filled that last of my ODD orders this morning at $39. Position is full, let's do this!
End buying any ODD? It’s sub 40 now.
Pfft, honestly that's why I post here. I enjoy researching companies and I view this as a place to help each other make money. Always make sure to your own research before you buy anything, even from me! lol I'm just a software engineer who likes to invest. Yeah, $NXT is a such a rad company. Thinking of moving into ODD soon too, have some capital. Also on the fence with $GILT, $MIND, and $PDEX. These ones are much smaller companies and are going to carry much more risk.
Yesterday I sold half my shares of NBIS, NXT, and FIX. Even though I'm long on all of them, they all seemed too above their fair value. Didn't know what I was holding the cash for until I saw ODD under 40 today. It's been falling for no great reason, and then more today on what I suspect is ELF earnings sympathy.
I'm still on the fence now with trying to go with ODD or EVER lol. Both are looking undervalued and solid businesses.
Kinda feeling that way about ODD too...
Finally pulled the trigger on BELFB this morning. Thinking finally opening a position ODD as well. BWAY has been on a nice little run of recent too.
Most interesting buys for me right now (for discussion). Trucking. I own HTLD, but there's tons of players. I think the next 1-3 years are set up to be really good for truckers, as I've posted about frequently. ODD. No idea why this sold off, other than weak consumer and technical trades. Mid teens EV/earnings and projecting 20% or more growth. NATL. About 6x forward earnings for a growing company that's buying back a ton of stock. Don't own this one yet, and I have no idea why. ABL. Everything is going great for these guys and the market has had no reaction. I'm excited for earnings in 11/5, but Q4 could put up obscene numbers based on a deal they just completed that will add ~$10 million in net income in Q4.
Peter Lynch move right there lol. I was about to start looking into the consumer reviews, since I'm now tempted to want to pull the trigger. I have like 1k that I want to move into something. Debating on a few names right now and ODD has now entered the chat.
ODD did an acquisition a few years ago that messed with their operating margin, so that might be what you're seeing. They also do various levels of marketing as they roll out new lines. I'm also wary of consumer brands, but the tipping point for me was my wife started using some of their stuff last year and loved it. It's nice to have a tester!
For sure. ODD always shows up my screener and I've looked into them before, just beauty makes me nervous after seeing what happened to OLPX. However, I am tempted to want to move into the company, just learning more about them. Only thing that sticks out with ODD to me is that the operating margins seems kind of wonky. The revenue growth is solid and the gross margins are pretty stable, but seems like operating is kind of all over the place. Yeah, CODA has been a nice little run.
If ODD hits $40, I'm backing up the truck.
The sheer amount of DNUT gaslighting, for just simply questioning, and identifying that maybe, just maybe, 151M shares being sold today, is a bit ODD… 151M? In a donut company? This isnt retail flows. Stop gaslighting us. Thanks
ODD possibly with a bottoming candle yesterday, right off the $50 support level. Added more at $50.5. nice move premarket today too.
ODD now trading at 3.5x P/C. 16x EV/FCF. And growing sales at 25% annually. No idea why, just slowly buying.
I bought ODD and ROOT, both are basically where I bought them yesterday morning and I still think both are cheap. So, fine I guess.
I like ODD also, but with retail being very disfavored isn’t there a chance it just gets pummeled indiscriminately with everything else?
ODD getting sold off as it fell below the 200 day. Now trading around 18x TTM EV/EBITDA. Sitting on a boatload of cash, guiding for 20%+ growth this year, and about to launch two new brands. I'm adding as soon as the chart bottoms.
Jefferies analyst Brian Tanquilut initiates coverage on ODDITY Tech (NASDAQ:ODD) with a Buy rating and announces Price Target of $78.
JMP Securities analyst Andrew Boone reiterates ODDITY Tech (NASDAQ:ODD) with a Market Outperform and maintains $80 price target.
So you're saying you have lvl 1 approval, and didn't understand you could be exercised and be short? Did you not read the ODD?
You're right, but they do tend to coalesce behind momentum names. There's some legit good ideas, but also a ton of followers that amplify whatever is working. I know I'm early to an idea if there's little to no discussion online about it. ODD still gets nearly zero following, for example. Ditto KFS.
I firmly believe that the "everything is expensive" crowd just doesn't look at enough names. OPRA: rule of 40 web browser trading at 16.5x earnings. Also pays a 5% dividend. NXT: utility solar isn't as rough as residential, and this gem is trading at 14.7x earnings. ODD: cosmetics name with 25%+ annual growth, trading at 22x EV/earnings. That's not even counting names with cheap forward earnings like CRMD (6x) or ABL (7x). Like Peter Lynch, turn over rocks.
ODD down to 22x EV/earnings. Closer to 20x at the low end of 2025 guidance (with history of under promises on guidance). Looking to add.
NE- offshore is sooooo cheap. AMTM - probably still about 25% upside this year ($30 price target for me). ODD- after today's selling, the valuation is more reasonable with new lines dropping later this year. ABL- waiting on the shorts to cover.
Closed TAP calls a little early, but turned out to be a decent play. Sentiment was too bombed out. UFPT having a nice run. Wouldn't be surprised to get a little short squeeze out of this one. The short report was actually right, but management seems to have proven adept at navigating things and made some nice acquisitions to counter slowing organic growth. Not surprised to see ODD selling off solid earnings. It was too expensive. That said, I'd love to add more if it retests the $50 level. I'm also curious what they'll do with their cash hoard. $815 million in cash on a $3.5 billion market cap is insane.
🥭 says RIGGED ELECTION like that bro says FAIRLY ODD PARENTS
ODD earnings: Net revenue was $241 million compared to $193 million in the second quarter of 2024, representing a 25% year-over-year increase. Gross profit was $174 million compared to $139 million in the second quarter of 2024, representing a 25% year-over-year increase. Gross margin was 72.3%, increasing by 10 bps compared to gross margin of 72.2% in the second quarter of 2024. Net income was $49 million compared to $45 million in the second quarter of 2024. Net income margin was 20.4% compared to 23.6% in the second quarter of 2024. Adjusted net income was $57 million compared to $51 million in the second quarter of 2024, representing a 12% year-over-year increase. Adjusted net income margin was 23.7% compared to 26.5% in the second quarter of 2024. Adjusted EBITDA was $70 million compared to $62 million in the second quarter of 2024, representing a 12% year-over-year increase. Adjusted EBITDA margin was 28.8%, decreasing by 350 bps compared to adjusted EBITDA margin of 32.3% in the second quarter of 2024. Diluted EPS were $0.79 for the second quarter of 2025 compared to $0.73 in the second quarter of 2024. Adjusted diluted EPS were $0.92 for the second quarter of 2025 compared to $0.82 in the second quarter of 2024. Cash and cash equivalents, restricted cash, short-term deposits and marketable securities were $815 million.
It really comes down to what the multiplier applies to. Everyone is telling me it applies to both premium and exercise without giving any source for that claim. I'm providing sources from OCC that state otherwise and it keeps getting ignored. Here's my source: [ODD](https://www.theocc.com/getmedia/a151a9ae-d784-4a15-bdeb-23a029f50b70/riskstoc.pdf)
The multiplier should only apply to the premium, not override the underlying shares. OCC clearly states that regardless of the multiplier, the exercise price should be calculated by the underlying shares. \`The exercise prices of the stock options that are traded at the date of this document are stated in U.S. dollars per share. The exercise price of an option must be multiplied by the number of shares underlying the option in order to determine the aggregate exercise price and aggregate premium of that option.\` From the ODD, page 18.
Keybanc analyst Aleksey Yefremov maintains ODDITY Tech (NASDAQ:ODD) with a Overweight and raises the price target from $65 to $90.
These might help you: [ODD](https://www.theocc.com/getmedia/a151a9ae-d784-4a15-bdeb-23a029f50b70/riskstoc.pdf) [Courses](https://www.optionseducation.org/theoptionseducationcenter/occ-learning)
BNED had some really large options purchased yesterday, which is strange for a thinly traded small cap. Meanwhile we're still waiting for earnings which will apparently be released eventually. Not sure if there's a connection between the two or not. I do think the algos are having a really hard time with this one due to the earnings mystery. ODD holding the $74-76 range far better than I thought it would. Certainly not cheap anymore, but this rally might be more than just shorts covering. I still think it retests $50 at some point though.
"He is an office in a public company, and government based business." So? How often do CEOs of public companies post their piss test results on twitter? It's ODD, and also proves 0, so an odd waste of time really.
You're very right. Position sizing is an often neglected tool. Not everything needs to be a massive position. I'm definitely getting more comfortable with buying smaller amounts initially. Like 2-3% makes a big impact of you're right, but not a huge impact if you're wrong. I feel like people also forget about trimming part of a position. Like ODD was a great buy at $40, it's a tenuous hold at $75. So I sold about a quarter of my shares. Just lock in some profits. Then you also get the ability to buy more of it gets cheap, and everything gets cheap occasionally.
Sold out of RSKD because I'd only put a small amount in and was able to reallocate the proceeds to ABL, which I think is an easy 40-50% upside in the near term. Just a better risk/reward profile coming off the short report. Also trimmed a few more shares of ODD at open. Rally is running out and the stock is really expensive. Still holding, just trimming. Will buy more if it retests the $50 level.
Oddity Finance LLC (the “Issuer”), a wholly-owned indirect subsidiary of ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its exchangeable senior notes due 2030 (the “Notes”) in a private placement As of March 31, 2025, ODDITY had $257 million in cash, and an undrawn $200 million credit line. Capital raise gives ODDITY additional firepower to play offense and pursue future opportunities in a volatile world. A portion of the proceeds will be used to purchase a hedge overlay intended to offset any share dilution up to a cap expected to be at least a targeted 100% premium to the stock price at pricing. Proceeds of the offering are not needed to support the ongoing business.
JP Morgan analyst Cory Carpenter maintains ODDITY Tech (NASDAQ:ODD) with a Overweight and raises the price target from $63 to $85.
The amount of no debt, low valuation names out of Israel is impressive. ODD of course, but I've also been looking at SPNS, RSKD, and one other nano cap. Adding this one too!
The fact that I'm not getting people with FOMO asking about ODD makes me really optimistic. It happened a lot with HMDPF.
ELF is going to drag down ODD. Just a feeling.
Yeah, it depends on the initial thesis. Like I own JXN because I think it's absurdly cheap. If it gets to the $160-170 range it's probably not and I'll sell. That's my whole thesis. Similar with the offshore drilling names. They should easily 5-6x or more in the next few years, but I'm happy to unload them at that point. Then there's the MELI, CSU, UFPT names. I don't plan to sell (barring obscene prices being offered because I firmly believe there's a theoretical price at which you should sell anything). This is the low maintenance part of my holdings. Then there's the not sure yet, but hope to hold them for a long time. NBIS and ODD are the two I'm riding now. I actually trimmed a few shares of ODD around $70. They're both promising and I'd love to hold for a really long time, but they're also smaller and speculative. These names tend to be good names to micromanage as they present opportunities to buy low and sell high because of their speculative nature. ODD will likely yield some chances to add later this year as they invest in new projects and probably see a wired earnings print or two. I'm definitely a fan of numbers, but also nuance. However, I do try to limit my total holdings. Anything I buy should be a better opportunity than something I own.
ODD down on big sale from CEO, hes locking in those gains
UFPT is gonna go nuts if this rally causes the shorts to cover. Probably not ODD levels of nuts, but still fun.
Sold a few more shares of ODD. It's pretty expensive now.
As with most things, we have to wade through a bunch of junk to get to something good. MELI was fantastic. TOITF was fantastic. I've been talking about ODD for months on here and it absolutely exploded after earnings. You're one of the ones that puts out interesting names at least, so thanks!
But you only follow WOLF for fun, I notice everyone I ask about says "STOCKS" to deflect but their comment history is 100% WOLF pumping; WOW HOW ODD. Bet you guys don't like that this how now become a freezone to poke holes in your scam stock.
Still almost no chatter online about ODD, even after this post earnings surge.
Totally. I think there's a lot of new shorts trying to make a name for themselves. Many of them are using public data. ODD had one last year that was basically just from looking at their website. The reason UFPT is down so much on the last few months is the fear of the ISRG business going away. To come out with a short report when the stock is already down 30% seems late to the party.
Now having that issue where i need to sell some names that have ran a bit too much (looking at you ODD). But not feeling great about buying this pump
ODD CFO on tariff impact: "Relative to other consumer companies, we are very well-positioned. We have an attractive gross margin structure, limited exposure to China directly, a robust and flexible supply chain, and great relationships with our global suppliers"
NU at $9.15 (35%) ODD at $38.5 (42%) My two big winners. The scary part, SPY is still below the 200 day. The intensity of that selloff can't be overstated. Just technically, we're still not in an uptrend.
Sold out of EVVTY at open. Great company, too many headwinds and there are other opportunities to buy right now. Yes, sold at a loss. Trimmed ODD at $60, just about the same amount of shares I bought in the $38+40 range a few weeks ago. Growing nicely out of speculation level sizing. Added NBIS. If management executes, I think this is a multi bagger, easy. Small position so far.
Posted on it last night, but the short squeeze on ODD is epically fun to hold. 17% if the float was short and the company just threw down 28% growth and raised guidance. Giddy up.
$ODD will be back below $54 by tomorrow
ODD earnings: First quarter net revenue of $268 million, up 27% year-over-year First quarter adjusted EBITDA of $52 million First quarter net income of $38 million and first quarter adjusted net income of $42 million First quarter operating cash flow of $88 million and free cash flow of $87 million Also, raised guidance. Soft launch of new brands late 2025.
He's thicker than pig shit. He also seems to me to display classic symptoms of Oppositional Defiant Disorder- if you tell him he should (or shouldn't) do something, he does the opposite- basically "I'll do whatever I want, you're not the boss of me!" It's very common in people with ADD and ADHD- I have ADHD and I 100% struggle with ODD.
[https://www.stocktitan.net/news/XAIR/neuro-nos-granted-fda-orphan-drug-designation-for-phelan-mc-dermid-33m03etvunbb.html](https://www.stocktitan.net/news/XAIR/neuro-nos-granted-fda-orphan-drug-designation-for-phelan-mc-dermid-33m03etvunbb.html) **FDA orphan drug designation brings regulatory benefits to XAIR's subsidiary for a rare disorder with no approved treatments, but clinical trials won't start until 2026.** The **FDA's Orphan Drug Designation** (ODD) for NeuroNOS's BA-102 represents a significant regulatory milestone for this **Beyond Air subsidiary**. This designation provides **tangible benefits** including **seven years of market exclusivity**upon potential approval, **tax credits** for qualified clinical trials, **waiver of FDA application fees**, and **access to FDA protocol assistance**. The designation targets **Phelan-McDermid Syndrome** (PMS), a rare genetic disorder with **no FDA-approved treatments** currently available. This creates a potential first-mover advantage in an uncontested treatment landscape. However, investors should note the **extended development timeline** \- first-in-human trials aren't planned until **2026**, indicating BA-102 is still in preclinical development. For Beyond Air, this regulatory recognition validates their subsidiary's research direction in the neurodevelopmental disorder space. The ODD benefits could reduce development costs and regulatory hurdles for this program, though it remains an early-stage asset with all typical drug development risks. The designation establishes a clearer regulatory pathway for a treatment addressing a recognized unmet medical need. https://preview.redd.it/wfy7xzg2y8we1.png?width=2741&format=png&auto=webp&s=afffc44b02db75293680ab52ab161a1bdc2b18db
I mean, of o have to make a prediction, I think S&P will rally. Shorts covering, oversold, etc. probably up to at least 5500. That's really the next test. Like I said, every trader was talking about closing shorts and going long on Friday. I'm fairly confident that's what's going on. I've been mostly adding to high conviction names. I bought NU premarket yesterday at like $9.15. I'm very happy buying there. I added some ODD at $38 on Friday. I'm very happy buying either at those prices. I still have some cash and a few names I might unload if we reject on the way up.
Because they aren't thinking. They're feeling. They've been cultivated into an adult version of ODD, and treat experts and science like a Cargo cult. https://www.additudemag.com/oppositional-defiant-disorder-in-adults/amp/ https://en.m.wikipedia.org/wiki/Cargo_cult They want things to be a certain way, and have been told "no, that's not how reality works" to their political views so much, they were given two choices. 1. Realize they were tricked and taken for marks, with all of their political beliefs being objectively bad for their own best interests (and have been for decades), and admit that, by their own metrics, experts in a field are... experts and should be listened to. 2. Double down and hope they can wish away all their bad feelings. Wish away all their shortcomings, and hope that things will be better, to whatever version of their nostalgia riddled memories that they want to happen again. Not actually put the work in to make them a reality, but just hope that by being bullies and throwing a tantrum, they'll come out on top.
Bulls have ADD, ADHD and ODD
HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- [Plus Therapeutics](https://www.globenewswire.com/Tracker?data=ORnlJKUz0Q5cLb9DaSMnach9NbW5otpANDcV9XhXhLudRHCgyIAOrr1JQhkciqyhnVLqhYn3NxghHCIRjp88L0dHfiWScWTDVcmH1UMU6rY=), Inc. (NASDAQ: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted [Orphan Drug Designation (ODD)](https://www.globenewswire.com/Tracker?data=0ZZVb92AfpJA7peB_KkTwFAAowp1tTJb6vDWYWj2c2KJiPdjW672tgKrHP7kXuCNyhw1g7JVF-2ubyEqlx3NU-j7VWtquWs5AFsSupKosDo4gjsz165o-RuOML9AxX0RVK1EPbWPDzgmb4l8QEzwDIRpG5SO6e4nb7FsKDk6AmyP8IXCcMZK8giRh91YMzk7) to Rhenium (^(186)Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.
ODD. Hit high 20% growth rates and guided for more of the same. 2 new product lines launching next year and an expansion of R&D to facilitate more growth in the future.
Notes from the ODD call (from X): Over 100% revenue repeat rate Q1 so far strong, seeing no weakness Brand 3 launch Q3, rollout in Q4. Computer vision (#AI) enabled. Not “me too”, targeting real consumer pain/ unserved markets. Oddity Labs 60 scientists building up to 100.
ODD earnings: Full year net revenue of $647 million, +27% year-over-year Full year adjusted EBITDA of $150 million, +40% year over year Full year net income of $101 million, full year adjusted net income of $121 million Full year net operating cash flow of $138 million and free cash flow of $134 million Fourth quarter net revenue of $124 million, +27% year-over-year Fourth quarter adjusted EBITDA of $15 million Fourth quarter net income of $5.3 million, fourth quarter adjusted net income of $12 million